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Background
Takayasu arteritis (TA) is a well known rare form of
large vessel vasculitis characterized by granulematous
inflammation. There are no controlled studies of medi-
cal treatment of children with TA.
Aim
Tumor necrosis factor (TNF) is the most important in
the formation of granulomas. The granulomatous nature
of the histopathologic lesion in TA led us to consider
an evaluation of the therapeutic benefits of anti-TNF
therapy in patients with refractory TA.
In our study five children (5 girls) aged from 10 to 17
years with widespread inflammation in the aorta and its
main branches were treated with infliximab during 6
months. The mean duration of the disease was 4.5
years. All patients received oral steroids and methotrex-
ate or cyclophosphamide. The cause for anti-TNF treat-
ment was standart therapy tolerance and uncontrolled
arterial hypertension. Patients were tested for tuderculo-
sis by skin test and chest roentgenography. Also we
excluded active systemic infections, neutropenia, throm-
bocytopenia and liver dysfunction.
Methods
The efficacy of infliximab therapy was evaluated by
inflammation markers – erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), fibrinogen, - clinical
symptoms and results of doppler ultrasound.
Results
The success of 3 months infliximab therapy was evalu-
ated according to the normal significances of ESP, CRP
and lack of active disease symptoms, after 6 months –
there were reduced of vessel wall thickness.
Conclusions
In children with refractory TA infliximab therapy was
associated with remission and facilitating dose reduction
of corticosteroids and other immunosuppressive treat-
ment. The presented experience justifies a randomized,
controlled clinical trial of anti-TNF treatment of TA in
children.
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